Diagnosis of prostate cancer in Serbia.

PURPOSE A rising incidence of prostate cancer is noticed in USA and Europe, which might be due to better diagnostic procedures and screening programs started in some countries. We still lack epidemiological studies confirming the same trend in our country, but the rising number of patients in whom radical prostatectomy is performed is an indirect proof of bigger recruitment of patients with prostate cancer. The purpose of this study was to establish the most appropriate diagnostic protocol for detection of prostate cancer in our unscreened population. MATERIALS AND METHODS Transrectal ultrasound (TRUS) -guided biopsies of the prostate were performed in 229 patients. Biplanar transrectal probe with needle channel was used. Six to 10 tissue cores were obtained from each patient. RESULTS The mean patients' age was 67.12 years (range 42-88). All patients had serum prostatic specific antigen (PSA) estimation before biopsy, which ranged from 0.41 to 1550 ng/ml (mean 50.83), with 146 (63.8%) patients having PSA level greater than 10 ng/ml. Free (F) PSA was performed in 120 (52.4%) patients; the range of F to total (T) PSA ratio was 0.02 to 0.74 (mean > 0.13). Digital rectal examination (DRE) was positive in 65% of the patients. The mean prostate volume was 40.5 ml (range 11-140). Cancer was diagnosed in 99 (43.2%) patients, prostate cancer in situ (PIN) alone was diagnosed in 37 (16.2%), chronic prostatitis in 73 (31.9%), while benign prostatic hyperplasia (BPH) was found in 20 (8.7%) patients. CONCLUSION The cancer detection rate in our patients was high. In a lot of patients the biopsy was needed only for histological proof, not as a staging tool, the intention of which is the selection of patients with localized prostate cancer amenable to curative treatment. There is still reluctance to use PSA as a sole indication for biopsy, positive DRE still being mandatory. With such a policy we are missing a lot of curable prostate cancer cases, thus increasing the cost of treatment. A national policy including screening should be considered.

[1]  T. Flam,et al.  Epidemiology of Prostatic Cancer , 1990, The Journal of international medical research.

[2]  S. Moss,et al.  Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional study , 2004, BJU international.

[3]  H. Nijs,et al.  Randomised Trial of Prostate Cancer Screening in the Netherlands: Assessment of Acceptance and Motives for Attendance , 1997, Journal of medical screening.

[4]  D. J. Pike,et al.  A seven-year follow-up of men following a benign prostate biopsy. , 2003, European urology.

[5]  Kazuto Ito,et al.  Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. , 2003, Urology.

[6]  R. van Mastrigt,et al.  Prostate volume ultrasonography: the influence of transabdominal versus transrectal approach, device type and operator. , 2004, European urology.

[7]  E. Horwitz,et al.  Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. , 2003, Urology.

[8]  J. Dale,et al.  Information needs and prostate cancer: the development of a systematic means of identification , 2004, BJU international.

[9]  P. Walsh.  Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. , 2000, The Journal of urology.

[10]  T. Wilt.  Prostate cancer: epidemiology and screening. , 2003, Reviews in urology.

[11]  J. Hugosson,et al.  Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. , 2004, European urology.

[12]  Adilson Prando,et al.  Baseline staging of newly diagnosed prostate cancer: a summary of the literature. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[13]  R. Pruthi.  The dynamics of prostate‐specific antigen in benign and malignant diseases of the prostate , 2000, BJU international.

[14]  O. Ogawa.  Risk Factors for Prostate Cancer , 2004 .

[15]  D. Gillatt,et al.  Case selection for radical prostatectomy in the UK. , 2004, European urology.

[16]  J. Moul,et al.  The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. , 2004, The Journal of urology.

[17]  B. G. Blijenberg,et al.  Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. , 2004, The Journal of urology.

[18]  J. McKiernan,et al.  Controversies in prostate cancer screening. , 2004, The Journal of urology.

[19]  F. Fabris,et al.  Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. , 2003, Critical reviews in oncology/hematology.

[20]  Robert W Veltri,et al.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. , 2003, The Journal of urology.

[21]  E. Negri,et al.  Leveling of prostate cancer mortality in Western Europe , 2004, The Prostate.

[22]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[23]  Theo M. de Reijke,et al.  Transrectal Ultrasound in the Diagnosis of Prostate Cancer: State of the Art and Perspectives , 2001, European Urology.

[24]  M. Luján,et al.  Prostate cancer detection is also relevant in low prostate specific antigen ranges. , 2004, European urology.

[25]  J. Fitzpatrick,et al.  Awareness of prostate cancer among the general public: findings of an independent international survey. , 2003, European urology.